drugset / Trial / NCT00929370

A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

NCT00929370

Phase 1 Terminated 34 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to understand safety and tolerability of the drug GSK1018921 after 14 days of dosing in healthy volunteers and then in patient volunteers.

Timeline

Start
2008-07
Primary completion
2008-10
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1018921 Unknown 80 mg
Subject GSK1018921 Unknown 200 mg

Indications